Foghorn Therapeutics Files 8-K

Ticker: FHTX · Form: 8-K · Filed: May 20, 2024 · CIK: 1822462

Foghorn Therapeutics Inc. 8-K Filing Summary
FieldDetail
CompanyFoghorn Therapeutics Inc. (FHTX)
Form Type8-K
Filed DateMay 20, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: sec-filing, 8-k

TL;DR

Foghorn Therapeutics filed a routine 8-K, no major news.

AI Summary

Foghorn Therapeutics Inc. filed an 8-K on May 20, 2024, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or material events beyond the standard reporting requirements.

Why It Matters

This 8-K filing indicates standard corporate reporting by Foghorn Therapeutics Inc. to the SEC, without disclosing new material events.

Risk Assessment

Risk Level: low — The filing is a standard 8-K report and does not contain any new material information that would indicate increased risk.

Key Players & Entities

  • Foghorn Therapeutics Inc. (company) — Registrant
  • 0001822462 (company) — Central Index Key
  • 001-39634 (company) — SEC File Number
  • May 20, 2024 (date) — Date of Report

FAQ

What is the primary purpose of this 8-K filing for Foghorn Therapeutics Inc.?

The primary purpose of this 8-K filing is to report a Regulation FD Disclosure and to file Financial Statements and Exhibits.

On what date was this 8-K report filed?

This 8-K report was filed on May 20, 2024.

What is Foghorn Therapeutics Inc.'s state of incorporation?

Foghorn Therapeutics Inc. is incorporated in Delaware.

What is the principal executive office address for Foghorn Therapeutics Inc.?

The address of the principal executive offices is 500 Technology Square, Ste 700, Cambridge, MA 02139.

Does this filing disclose any new material events or financial results?

Based on the provided text, this filing appears to be a standard reporting document and does not explicitly disclose new material events or specific financial results beyond the reporting categories.

Filing Stats: 495 words · 2 min read · ~2 pages · Grade level 11.4 · Accepted 2024-05-20 08:02:04

Key Financial Figures

  • $0.0001 — ge on which registered Common Stock, $0.0001 par value per share FHTX The Nasdaq Glo

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. Foghorn Therapeutics Inc. (the "Company") is furnishing as Exhibit 99.1 to this Current Report on Form 8-K a presentation dated May 20, 2024, which the Company intends to use in meetings with or presentations to investors. The information in this Item 7.01 (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Investor Presentation dated May 20, 2024

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. FOGHORN THERAPEUTICS INC. By: /s/ Kristian Humer Kristian Humer Chief Financial Officer Date: May 20, 2024

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.